Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price ...
The top barrier to AI adoption among pharma commercial leaders is compliance uncertainty, and the fix may be governance that ...
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational ...
Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.
Shionogi’s Dr. Draica on why preventative antivirals matter — and how its HIV and flu prevention heritage shaped XOCOVA’s post-exposure focus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results